Greg Madison is a seasoned executive who brings strong operating experience and a track record of success leading small to medium-sized organizations. Prior to joining Shield, he was Chief Executive Officer at Melt Pharmaceuticals in Boston, MA, a company developing a sublingual formulation of midazolam and ketamine, providing needle and opioid-free procedural sedation and analgesia. Prior to Melt Pharmaceuticals, he was Chief Executive Officer of Keryx Biopharmaceuticals from 2015 to 2018, where he led the transformation of the organization from development stage to commercial stage focused on Auryxia